Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) XXXX .

@entity1 @entity137 @entity1697 @entity5 @entity900 @entity418 @entity1487
PURPOSE: In 1991, we started a clinical prospective trial for operable @entity418 , foreseeing organ preservation, to assess the treatment results after definitive chemoradiotherapy (CRT) for clinical Stage I (T1N0M0) @entity418 . @entity1 AND METHODS: Between 1992 and 2003, 63 @entity1 were enrolled in this study. @entity5 depth was @entity1697 (T1a) in 23 and @entity5 (T1b) in 40. CRT consisted of 55-66 Gy/50-60 fractions (median, 59.4 Gy); from 1 to 3 cycles (median, 2) of concurrent chemotherapy ( @entity900 and @entity1487 ), followed by high-dose-rate intraluminal brachytherapy 10-12 Gy/2-3 fractions. RESULTS: The 5-year overall and cause-specific and disease-free survival rates were 66.4%, 76.3%, and 63.7%, respectively. The 5-year cause-specific survival rates for T1a and T1b @entity5 @entity1 were 85.2% and 70.0%, respectively (p = 0.06). The 5-year disease-free survival rates for T1a and T1b were 84.4% and 50.5%, respectively (p < 0.01). Esophageal fistula as a late @entity137 occurred in 2 @entity1 (G4: 1; G5: 1), and esophageal stricture requiring a liquid diet occurred in 2 @entity1 . Pericardial effusion was observed in 3 @entity1 . CONCLUSION: We confirmed that @entity1 with T1N0M0 @entity418 had their esophagus preserved in 89.2% of cases after definitive CRT, and the survival rates were equivalent to those of previous reports of surgery.
